Karyopharm Therapeutics INC DEF 14A proxy statements

Karyopharm Therapeutics Inc. announced its 2026 Annual Meeting of Stockholders, scheduled for May 21, 2026, to elect directors and vote on equity plan amendments.

Karyopharm Therapeutics Inc. will hold a special stockholder meeting on February 18, 2026, to vote on a proposal to significantly increase its authorized common stock to facilitate future capital raising and strategic initiatives.

Karyopharm Therapeutics is asking shareholders to vote on key proposals, including amendments to equity incentive plans and a stock option exchange program, at its upcoming annual meeting.

Karyopharm Therapeutics is asking stockholders to approve an amendment to its 2022 Equity Incentive Plan to increase the number of shares available for issuance by 450,000.

Karyopharm Therapeutics Inc. will hold its annual meeting on May 29, 2024, to vote on director elections, equity incentive plan amendments, a stock option exchange program, executive compensation, and auditor ratification.

Karyopharm Therapeutics is asking stockholders to approve amendments to its equity incentive and employee stock purchase plans, as well as a one-time stock option exchange program for non-executive employees.